Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
about
Bispecific antibodies and their applicationsLooking up: Recent advances in understanding and treating peritoneal carcinomatosisEmerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachTranslating basic mechanisms of IgG effector activity into next generation cancer therapiesAntibody-based immunotherapy for ovarian cancer: where are we at?Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cellsRelationship between epithelial cell adhesion molecule (EpCAM) overexpression and gastric cancer patients: A systematic review and meta-analysisThe development of bispecific antibodies and their applications in tumor immune escape.Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesTarget Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins.Have we overestimated the benefit of human(ized) antibodies?Malignant ascites: pathophysiology and treatment.Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.Rapid optimization and prototyping for therapeutic antibody-like molecules.HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.ZEB1-responsive genes in non-small cell lung cancerDeterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesBiodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor siteOutpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.Cancer stem cells: a new framework for the design of tumor therapies.Dual targeting strategies with bispecific antibodies.EpCAM and its potential role in tumor-initiating cells.Catumaxomab: in malignant ascites.Role of the EpCAM (CD326) in prostate cancer metastasis and progression.
P2860
Q26774024-B3C83267-41B3-41AE-B3EC-120820779D5EQ26849259-C8BF5CA7-163E-4063-80F9-6E9AEBFDB8D8Q26849477-175695D6-5128-4DCB-AF51-4AFA735956DAQ26991899-F107ABB4-6143-41CB-94B7-4A22FF595DACQ27000514-18B17F30-6986-4B6F-A57C-D036EBF4692CQ27316983-3E8F78D6-491F-49CC-ACB2-551F005775BFQ31149698-FAE2BD3D-2B2E-4166-8D6C-088CF4313285Q33558687-6366C5CE-B3ED-424C-B110-27065B3A71C4Q33630292-6AE59717-FA65-4B04-84B3-90A3F3C3A6FEQ33648086-9023D01E-DB13-442D-BB00-E8DEDA8DACFFQ33755476-2822908A-AC6F-4837-A8A0-59A7CF2AB7AEQ33771039-3CC456CE-AED3-4CA9-B80C-EBC393485D28Q34142714-D053F190-1A1A-4F30-A067-2245792CE080Q34213359-DB4DC4F2-C555-47A2-AC43-512AEB66ED00Q34404833-8E62E0A2-134F-49B7-8AC0-FDCFD13DAA47Q34548319-E53D044D-252A-450F-99C8-6107FDBF5627Q34570056-5253EB55-6E9B-4A81-A7DE-3C86DB14F6D7Q34580658-10E304A3-EBCB-475A-A4AE-0A8733617B53Q34981712-3636741B-2B7A-4AC8-B8A7-ADFCBA82FBDFQ35119802-B5369B76-D0F8-4FB0-81A5-C4E8FA4EC611Q35199371-246F7BB1-A590-4DFE-95AD-E628EDC4FD59Q35556641-1CFCCF9B-3EB5-4DA8-B3F2-F4DAEEDF2E45Q35628492-418420E0-4648-406A-8D98-F95276601F77Q35915752-FE77CDBC-F53A-4CAA-BD14-691EC1F382A3Q36112029-31F9ABF5-87DF-437E-AC63-5AE8659AE61EQ36153347-0EB78261-5092-40AE-9AE7-0884CB3E33AAQ36411863-DB7E419E-3DE4-4155-AAF2-FA8FF09E4FF0Q36478769-6D815991-CB42-4AC3-BBD8-D51DFACA54B0Q36797398-18863FB5-579B-4FE8-801E-61EE99836F94Q37225693-17BE9453-934B-4E21-A5AA-281B516C2B8EQ37287006-1F2EDCD6-A60B-4347-BAA9-40CACC3C10B4Q37317487-95308F91-BFF9-49CC-832F-6BCAFE229D5EQ37698921-D12E293E-690B-4456-9182-7527FAC5B838Q37706213-19D957A2-CFEF-46E3-A82D-1DC212AB1D63Q37716015-7D4E4D54-E0B7-497A-A3F9-13ECE9C92A35Q37796629-1FC4A54F-9598-43C6-95CB-71AD64246787Q37997559-9574BDD6-6667-4CAC-95C5-C5F14934609BQ38014664-BA9CE774-AAA5-4A05-B9B4-6658006B15C4Q38016957-8730F428-06F2-427D-AC83-41D5EE7D47D8Q38020426-ADF646AA-B188-41C2-A351-19DDAD40CD68
P2860
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Development and approval of th ...... targeted cancer immunotherapy.
@ast
Development and approval of th ...... targeted cancer immunotherapy.
@en
Development and approval of the trifunctional antibody catumaxomab
@nl
type
label
Development and approval of th ...... targeted cancer immunotherapy.
@ast
Development and approval of th ...... targeted cancer immunotherapy.
@en
Development and approval of the trifunctional antibody catumaxomab
@nl
prefLabel
Development and approval of th ...... targeted cancer immunotherapy.
@ast
Development and approval of th ...... targeted cancer immunotherapy.
@en
Development and approval of the trifunctional antibody catumaxomab
@nl
P2093
P1476
Development and approval of th ...... targeted cancer immunotherapy.
@en
P2093
Carsten Bokemeyer
Diane Seimetz
Horst Lindhofer
P304
P356
10.1016/J.CTRV.2010.03.001
P577
2010-03-27T00:00:00Z